VEGFA and age-related macular degeneration: In 2004, the FDA approved the first therapeutical aptamer pegaptanib sodium (Macugen), an RNA-modified aptamer conjugated to polyethylene glycol (PEG), aimed for intravitreal injection, acting as antagonist of vascular endothelial growth factor (VEGF) indicated for the treatment of age-related macular degeneration [5,6].